Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39976 | 0.67 | CYP2C9 (0.42) | EPHX1HSD11B1CYP2C9EPHX2 | |
| Lithium SCHEMBL5510213 | 0.65 | CYP2C9 (0.40) | EPHX1HSD11B1CYP2C9EPHX2 | |
| SCHEMBL26048194 | 0.64 | ATM (0.42) | — | |
| SCHEMBL14409931 | 0.64 | ATM (0.42) | — | |
| SCHEMBL6862681 | 0.63 | HSD11B1 (0.35) | EPHX1HSD11B1CYP2C9EPHX2 | |
| SCHEMBL814158 | 0.63 | HSD11B1 (0.35) | EPHX1HSD11B1CYP2C9 | |
| SCHEMBL1048761 | 0.63 | HSD11B1 (0.35) | EPHX1HSD11B1CYP2C9EPHX2 | |
| SCHEMBL10584202 | 0.63 | CYP2C9 (0.38) | EPHX1HSD11B1CYP2C9 | |
| SCHEMBL1238711 | 0.63 | CYP2C9 (0.38) | EPHX1HSD11B1CYP2C9 | |
| SCHEMBL251015 | 0.63 | CYP2C9 (0.38) | EPHX1HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | GABRA5, GABRA1, GABRA4 | EPHX1 1850/4885HSD11B1 2250/4885CYP2C9 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.